To the Editor: Leuprolide is a synthetic luteinizing hormonereleasing hormone (LHRH) agonist used in the treatment of advanced prostate cancer. It is available as an immediate-release intramuscular injection, a depot suspension for intramuscular injection, and an extended-release suspension for subcutaneous injection. After a 45-mg dose of subcutaneous leuprolide, 99.1% of patients experience clinical castration by day 28, defined as serum testosterone levels < 50 ng/mL. 1 In addition to this decrease in serum testosterone levels, decreases in sex hormone-binding globulin and estradiol are also seen. 1,2 Although there have been reports 3,4 of emotional lability, depression, and anxiety with LHRH agonists, the data are not consistent. Furthermore, all published reports on psychiatric side effects of LHRH agonists have been exclusively in female patients. The package insert 1 of leuprolide depot subcutaneous injection does list anxiety, depression, and delusions as occurring in less than 5% of patients. Here, we describe a case of a 65-year-old man with no prior psychiatric history who developed manic and psychotic symptoms after receiving a 45-mg subcutaneous injection of leuprolide. This is the only case available in the literature that describes a male patient experiencing such severe psychiatric symptoms in association with leuprolide.Case report. Mr A, a 65-year-old white man, was brought into the emergency department by the police after they were called by his wife. She reported that he was extremely agitated, shouting profanities, threatening her, and accusing her of being schizophrenic. Over the last 3 to 4 weeks, he had been progressively sleeping less, only sleeping 1 to 2 hours per night immediately prior to admission. He had persecutory delusions regarding the Mafia and FBI. He was hyperverbal, had pressured speech, and was repeatedly quoting the Bible. Over the past several weeks, he had been displaying bizarre behavior, such as impulsively buying objects he had no use for and excessively spending money. He had also been irritable with his wife and using profanity, which was unusual behavior for him. At the time of admission, an accurate history could not be obtained
Hereditary haemochromatosis is the most common inherited disorder in white populations, whereas non-alcoholic steatohepatitis (NASH) is becoming the most common reason for referral for investigation of abnormal liver function tests (LFTs). This report describes two sisters, from similar environments, who were referred to the clinic after being found to be C282Y homozygotes and to have abnormal LFTs. One sister had developed features of haemochromatosis and the other had developed NASH. These cases illustrate the potential non-penetrance of HFE gene mutations and the need to investigate abnormal LFTs fully, even when there is a positive genetic test at the outset.T he two sisters both presented to the gastroenterology clinic at a district general hospital. CASE 1ER, a 48 year old woman, was referred to the clinic for the investigation of abnormal LFTs. Her father had died from a hepatoma; he had no previously known liver complaints, but had developed diabetes and a tanned complexion in his last years. After his death, ER investigated his medical history with the help of the internet, and becoming concerned that her father might have died from complications arising from undiagnosed haemochromatosis, consulted her general practitioner.She had no relevant past medical history, was taking no medication and, apart from her father's history, had no risk factors for liver disease. In addition, she had a normal menstrual history.On examination she appeared well. Her body mass index (BMI) was 24 and there were no stigmata of chronic liver disease.Investigations revealed mildly deranged LFTs, with the only abnormalities being an aspartate aminotransferase (AST) of 55 U/litre (normal, , 25) and c glutamyl transpeptidase (cGT) of 57 U/litre (normal, , 50). Autoantibody screening and viral serology were both negative. Both serum ferritin and transferrin saturation were raised at 981 mg/litre (normal range, 18-300) and 73 mg/litre (normal range, 15-45), respectively. Genotyping revealed that she was homozygous for the C282Y mutation of the HFE gene (and wild-type for the H63D mutation). Liver biopsy (fig 1) revealed features in keeping with haemochromatosis; the calculated hepatic iron index was 2.62 mmol/g/year (normal, , 1.9), supporting the overall diagnosis of genetic haemochromatosis. CASE 2CR, a 53 year old woman and elder sister of ER, was subsequently referred to the same clinic. Both sisters had lived on the same street since leaving their childhood home. After being alerted by her sister's problems, she visited her general practitioner and was found to have abnormal LFTs and to be homozygous for the C282Y mutation (and wildtype for the H63D mutation).She had a past history of ischaemic heart disease, type 2 diabetes, hypothyroidism, and osteoarthritis of the hip. Her current medications were aspirin, isosorbide mononitrate, lisinopril, metformin, thyroxine, and dihydrocodeine. She consumed less than 10 units of alcohol each week, had no risk factors for viral hepatitis, and had a normal past menstrual history.On exam...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.